Signaling Pathways and Mechanisms in Cancer Therapy Resistance

Dear Colleagues,

Acquired therapy resistance in cancer cells substantially confines the clinical effectiveness of targeted anticancer therapies. The evolution of therapy resistance is coordinated by the ongoing acquisition of genetic, epigenetic, molecular, and microenvironmental modifications. These unique or synchronized modifications lead to the activation of diverse yet functional signaling pathways that dictate the development of resistance to treatments. Moreover, the cellular signaling of therapy resistance in interdisciplinary collaborations with nanomedicine, immunology, experimental therapeutics, cancer stem cell biology, and energy metabolism covers an essential element in translational drug development research. The growing interest in this field of cancer therapy resistance, uniquely composed of complex molecular circuits in cancer cell types, has resulted in the emergence of innovative research areas that cover molecular targeting and explore the impact of lineage selection and/or transformation, differentiation, survival advantage, and dissemination to combat therapy resistance.

In this Special Issue, we aim to collate original research and review articles that address the current landscape of cellular signaling and mechanisms in cancer therapy resistance, including genetic and epigenetic modifications in therapy resistance, signaling pathways controlling resistance, pathways directed for targeted experimental therapies, and research addressing cancer cell therapy resistance.

Dr. Natarajan Aravindan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer therapy
• therapy resistance
• molecular mechanisms
• cell signaling pathways
• genetic and epigenetic modifications
• combination therapies